Results 101 to 110 of about 211,280 (349)

To clot, or not to clot – Antithrombotic therapy is the question

South African Family Practice, 2019
Haemostasis and thrombosis rely on three components namely the vascular endothelial wall, blood platelets and the coagulation cascade. Non-physiologic excessive thrombosis occurs when haemostatic processes are dysfunctional, causing undue clot formation ...
E. Osuch, A. Marais
doaj   +1 more source

Exposure to CYP2C19‐metabolized drugs following acute stroke: A longitudinal cohort study to inform implementation of CYP2C19 genotype testing

British Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 2C19 (CYP2C19) genotype testing is recommended to guide antiplatelet selection after ischaemic stroke and transient ischaemic attack. CYP2C19 also metabolizes several commonly prescribed non‐antiplatelet drugs. We aimed to quantify exposure to CYP2C19‐metabolized drugs in stroke patients at hospital discharge and during ...
Cleodie C. Swire, Andrew T. Lambarth, Ayesha Saleem, Daniel R. Burrage   +3 more
wiley   +1 more source

Atractylodes lactone compounds inhibit platelet activation

Platelets, 2017
Platelets play a crucial role in the development and progression of atherosclerosis-thrombosis and, therefore, antiplatelet drugs are widely used in the treatment of coronary artery disease. Moreover, advances in understanding the biological functions of
Yizhu Chen, Wenlong Yang, Lingyu Guo, Xiaolin Wu, Tiantian Zhang, Junling Liu, Junfeng Zhang   +6 more
doaj   +1 more source

ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison.

Journal of the American College of Cardiology, 2018
Dual antiplatelet therapy (DAPT) is the cornerstone of pharmacological treatment aimed at preventing the atherothrombotic complications in patients with a variety of coronary artery disease (CAD) manifestations.
D. Capodanno, F. Alfonso, G. Levine, M. Valgimigli, D. Angiolillo   +4 more
semanticscholar   +1 more source

Newer agents in antiplatelet therapy: a review

, 2012
Jennifer Yeung, Michael HolinstatCardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USAAbstract: Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in ...
Yeung J, Holinstat M
core  

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source

Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy

British Journal of Clinical Pharmacology, EarlyView.
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou, Alexander T. Cohen, Lucy Vernon, Victoria Collings, Ubonphan Chaichana, Natasha Moore, Hamda Jibril, Li Wei, Nicola Kumar, Karen A. Breen, Andrew J. Doyle   +10 more
wiley   +1 more source

Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study

The Lancet, 2017
Summary Background Lifelong antiplatelet treatment is recommended after ischaemic vascular events, on the basis of trials done mainly in patients younger than 75 years.
Lin-Xin Li, O. Geraghty, Z. Mehta, P. Rothwell   +3 more
semanticscholar   +1 more source

Antiplatelet Agents

, 2018
Antiplatelet agents are commonly used in vascular medicine and cardiology, but also in the pharmacologic management of patients with ischemic stroke. Aspirin alone remains the mainstay of therapy for secondary stroke prevention.
Sarah L. Clark, Eelco F. M. Wijdicks
core   +1 more source

Republished: Antiplatelet therapy for secondary prevention of coronary artery disease [PDF]

, 2015
The choice and duration of antiplatelet therapy for secondary prevention of coronary artery disease (CAD) is determined by the clinical context and treatment strategy.
Windecker, Stephan, Pilgrim, Thomas
core   +1 more source